Loading patent…
AssigneeShanxi Medical University
InventorsYi Zhang, Huan Xue, Min Zhang, ZhiHong Lu, Linping Zhi, Zhitong Wen, Lijuan Cui, Tao Bai, Yunfeng Liu
Estimating the term…
The present invention relates to an anisomycin derivative represented by general formula (I) or pharmaceutically acceptable salts, solvates and stereoisomers thereof. According to the present invention, it is found that anisomycin and derivatives thereof have the effect of promoting insulin secretion under high blood sugar concentrations, and can treat diabetes and prevent the occurrence of hypoglycemia. It is found, by studying its mechanism of action, that the anisomycin derivative is highly related to GLP-1R, indicating that the anisomycin derivative is a small molecule GLP-1R agonist, which can effectively treat a variety of GLP-1R-mediated diseases including obesity and diabetes, and has good commercial application prospects and scientific research value.
A method for treating diabetes in a subject, comprising administrating a therapeutically effective amount of a GLP-1R agonist to said subject, wherein the GLP-1R agonist comprises, as an active ingredient, one or more compounds selected from anisomycin, a compound of formula I, a compound of formula II, and pharmaceutically acceptable salts thereof,
A pharmaceutical composition for treating, comprising an effective amount of an active ingredient selected from anisomycin, a compound of formula I, a compound of formula II, and pharmaceutically acceptable salts thereof,
Dependencies are inferred from the claim text.